POINT Biopharma Strengthens Senior Management Team with Appointment of Dr. Myra Rosario Herrle as EVP, Regulatory Affairs
June 28, 2021 07:00 ET
|
POINT Biopharma
INDIANAPOLIS, June 28, 2021 (GLOBE NEWSWIRE) -- POINT Biopharma Inc. (POINT), a global radiopharmaceutical company dedicated to advancing precision radioligand therapy for the treatment of cancer,...
POINT Biopharma Announces First Patients Dosed in Phase 3 Study of PNT2002 for mCRPC
June 04, 2021 06:30 ET
|
POINT Biopharma
INDIANAPOLIS, June 04, 2021 (GLOBE NEWSWIRE) -- POINT Biopharma Inc. (POINT), a global radiopharmaceutical company dedicated to successfully delivering precision radioligand therapy to cancer...
POINT Biopharma Receives U.S. Nuclear Regulatory Commission Materials License for Indiana Facility
April 28, 2021 07:00 ET
|
POINT Biopharma
INDIANAPOLIS, April 28, 2021 (GLOBE NEWSWIRE) -- POINT Biopharma Inc. (POINT), a radiopharmaceutical company dedicated to bringing the many benefits of precision radioligand therapy to cancer...
POINT Biopharma and TerraPower Sign Supply Agreement for Actinium-225
March 23, 2021 07:00 ET
|
POINT Biopharma
TORONTO, March 23, 2021 (GLOBE NEWSWIRE) -- POINT Biopharma Inc. (POINT), a radiopharmaceutical company dedicated to bringing the many benefits of precision radioligand therapy to cancer patients,...
Next-generation Radiopharmaceuticals Company POINT Biopharma to list on NASDAQ through merger with Research Alliance Corp. I
March 15, 2021 06:00 ET
|
POINT Biopharma
POINT Biopharma has entered into a definitive merger agreement with Research Alliance Corp. I (Nasdaq: RACA). Upon closing, the combined company is expected to be listed on Nasdaq under the ticker...
POINT Biopharma Signs Exclusive License Agreement with CanProbe for the Commercialization of a Neuroendocrine Tumor Treatment
January 12, 2021 07:00 ET
|
POINT Biopharma
TORONTO, Jan. 12, 2021 (GLOBE NEWSWIRE) -- POINT Biopharma Inc. (POINT), a radiopharmaceutical company dedicated to bringing the many benefits of precision radioligand therapy to cancer patients,...
POINT Biopharma Announces New Board Appointments
December 09, 2020 07:00 ET
|
POINT Biopharma
Jonathan Ross Goodman, Gerry Hogue and Peggy Gilmour join POINT’s Board of Directors TORONTO, Dec. 09, 2020 (GLOBE NEWSWIRE) -- POINT Biopharma Inc. (POINT), a radiopharmaceutical company dedicated...
POINT Biopharma and Bach Biosciences announce licensing and partnership for canSEEK™ pan-cancer targeting technology
November 10, 2020 07:00 ET
|
POINT Biopharma
POINT Acquires exclusive rights to breakthrough pan-cancer treatment TORONTO and BOSTON, Nov. 10, 2020 (GLOBE NEWSWIRE) -- POINT Biopharma Inc. (POINT) today announced that it has entered into a...
POINT Biopharma Presents at 2020 BIO Investor Forum
October 13, 2020 07:00 ET
|
POINT Biopharma
TORONTO, Oct. 13, 2020 (GLOBE NEWSWIRE) -- POINT Biopharma Inc. (POINT), a radiopharmaceutical company dedicated to bringing the many benefits of precision radioligand therapy to cancer patients,...
POINT Biopharma Further Strengthens Executive Team with Key Clinical and Financial Members
August 25, 2020 07:00 ET
|
POINT Biopharma
TORONTO, Aug. 25, 2020 (GLOBE NEWSWIRE) -- POINT Biopharma Inc. (POINT), a radiopharmaceutical company dedicated to bringing the many benefits of precision radioligand therapy to cancer patients, is...